BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 19

Takeda Pharmaceutical Co Ltd

TAKNYSE
Trade with Public
Trade with Public
$18.91
-0.14-0.73%
가까이에: Sep 18, 5:00 PM EST
$18.96
0.050.26%
시간외: 4:11 PM EST
배당금: 배당락일은 11일 후입니다
개요뉴스실적 전망이벤트재무심리지분 현황배당금비교옵션주식 보고서

Takeda Pharmaceutical Co Financials

Takeda Pharmaceutical Co (TAK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.
Benzinga Newsdesk

PRO
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Benzinga Newsdesk

PRO
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 7.69 percent decrease over earnings of $0.52 per share from
Benzinga Newsdesk

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK's late-stage pipeline and 2026 forecasts.
Vandana Singh

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.

Takeda Pharmaceutical Co (NYSE:TAK) is looking for FY2026 GAAP EPS of $0.66.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved